Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI311 Phase 1 Dose Escalation in Healthy Volunteers
NCT05480579Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sycume in thyroid eye disease (TED) (5 arms), sponsored by Innovent Biologics. Primary endpoint: Incidence, relatedness and severity of all adverse events, treatment emergent adverse events and serious adverse events up to 16 weeks. Started Aug 2022; status: completed.
02
Drugs
sycume
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT05480579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05480579.